Listed by the USPTO as GONZALEZ, LUISALBERTO
Tech Center 1600 • Art Units: 1624 1626 1632
This examiner grants 60% of resolved cases
GONZALEZ, LUISALBERTO is assigned to tech center 1600 and art unit 1624. The profile records 159 resolved cases, a 59.7% allowance rate, and a median of 1061 days to allowance. The figures indicate that applicants should allow for continued prosecution work while maintaining a schedule that accommodates more than a short examination cycle.
Interviews correspond to a 46.3% allowance lift, making direct discussion a potentially important part of response planning. Counsel may prepare interviews around specific distinctions, proposed amendments, and a clear path toward allowable subject matter. The leading companies are Orcosa Inc., Syngenta AG, and SK Inc. The firms listed are FISH & RICHARDSON P.C. (TC), PATTERSON + SHERIDAN, L.L.P., and BakerHostetler.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18575717 | USE OF FLUAZIFOP-P-BUTYL FOR INSECT CONTROL | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 17431499 | USE OF SPIROPIDION | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18552055 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 19347194 | METHODS FOR TREATING ALZHEIMER DISEASE AND FOR REDUCING AMYLOID BETA FORMATION | Final Rejection | SK CHEMICALS Co., Ltd. |
| 18436306 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18671224 | ORGANIC MOLECULE LIGHT EMITTERS | Non-Final OA | The Governing Council of the University of Toronto |
| 18683106 | COMPOSITIONS FOR ORGAN AND TISSUE PRESERVATION | Non-Final OA | Yale University |
| 18571471 | ANTI-CANCER COMPOUNDS AND METHODS OF USE | Final Rejection | YALE UNIVERSITY |
| 18611505 | Substituted Bimane Compounds and Methods of Use Thereof | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18703125 | COMPOSITIONS AND METHODS FOR TARGETING GPCR FOR THE PREVENTION AND TREATMENT OF PAIN | Non-Final OA | Duke University |
| 18575414 | CRYSTALLINE FORMS OF 3-{4-[(2R)-2-AMINOPROPOXY]PHENYL}-N-[(1R)- 1-(3-FLUOROPHENYL) ETHYL]IMIDAZO[1,2-B]PYRIDAZIN-6-AMINE AND SALTS THEREOF | Final Rejection | Nuvation Bio Inc, |
| 18565690 | METHODS FOR TREATING MULTIPLE SCLEROSIS | Non-Final OA | Vanda Pharmaceuticals Inc. |
| 18575454 | NEW METHOD TO TREAT ACIDOSIS RELATED DISEASES WITH ACETOACETATE | Non-Final OA | CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS |
| 18256295 | BIO PESTICIDAL COMPOSITION CONTAINS NOVEL NONANOATE ESTERS OF SUGARS AND SUGAR ALCOHOLS TO CONTROL LEPIDOPTERA, HEMIPTERA AND THYSANOPTERA INSECTS | Non-Final OA | FERTIS INDIA PVT. LTD. |
| 18033292 | FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | Non-Final OA | GenEros Biopharma Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy59.7% of resolved applications examined by Luisalberto Gonzalez were allowed (159 resolved cases), compared with 54.6% across Art Unit 1624 over the last five years.
This examiner's interview lift is +46.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Luisalberto Gonzalez took 1,061 days on average from filing to allowance.
Luisalberto Gonzalez examines applications in Art Unit 1624 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
